American Association for Cancer Research

Molecularly Targeted Therapies: Mechanisms of Resistance

Molecularly Targeted Therapies: Mechanisms of Resistance 2012Molecularly Targeted Therapies:
Mechanisms of Resistance
May 9-12, 2012
The Westin San Diego
San Diego, CA

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
Mace L. Rothenberg, Pfizer, New York, NY

This inaugural Special Conference on Molecularly Targeted Therapies on mechanisms of resistance drew over 350 researchers and scientists from more than 25 countries. The exciting program addressed the question of how certain proliferating cells fail to respond to certain therapies and explored the biologic and genetic causes for variations in tumor behavior. Researchers from academia, government and industry contributed to this important program to further our understanding of cancer drug resistance and the implications for new treatments.

* Adobe Acrobat Reader required

Please visit the AACR Meetings & Workshops Calendar for a complete list of upcoming programs.



Eli Lilly and Company          Genentech - A Member of the Roche Group


Amgen          Bristol-Myers Squibb

Celgene          Gilead


Aflac, Inc.          NCI Center to Reduce Cancer Health Disparities